A citation-based method for searching scientific literature

Chaojie Feng, Minxiang Wu, Zhengyue Chen, Xiongwei Yu, Zhenyu Nie, Yu Zhao, Beiyan Bao. Int Urol Nephrol 2019
Times Cited: 6







List of co-cited articles
23 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N Engl J Med 2019
66

Renal, metabolic and cardiovascular considerations of SGLT2 inhibition.
Ralph A DeFronzo, Luke Norton, Muhammad Abdul-Ghani. Nat Rev Nephrol 2017
213
66

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
50

Amelioration of diabetic nephropathy by SGLT2 inhibitors independent of its glucose-lowering effect: A possible role of SGLT2 in mesangial cells.
Toshinobu Maki, Sayaka Maeno, Yasutaka Maeda, Mayumi Yamato, Noriyuki Sonoda, Yoshihiro Ogawa, Masanori Wakisaka, Toyoshi Inoguchi. Sci Rep 2019
31
33


Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Christoph Wanner, Silvio E Inzucchi, John M Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Bernard Zinman. N Engl J Med 2016
33

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.
J-F Yale, G Bakris, B Cariou, J Nieto, E David-Neto, D Yue, E Wajs, K Figueroa, J Jiang, G Law,[...]. Diabetes Obes Metab 2014
165
33

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
33

Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program.
Brendon L Neuen, Toshiaki Ohkuma, Bruce Neal, David R Matthews, Dick de Zeeuw, Kenneth W Mahaffey, Greg Fulcher, Qiang Li, Meg Jardine, Richard Oh,[...]. J Am Soc Nephrol 2019
50
33

SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: A systematic review and meta-analysis.
Samuel Seidu, Setor K Kunutsor, Xavier Cos, Syed Gillani, Kamlesh Khunti. Prim Care Diabetes 2018
37
33

Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.
Ofri Mosenzon, Stephen D Wiviott, Avivit Cahn, Aliza Rozenberg, Ilan Yanuv, Erica L Goodrich, Sabina A Murphy, Hiddo J L Heerspink, Thomas A Zelniker, Jamie P Dwyer,[...]. Lancet Diabetes Endocrinol 2019
252
33

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
33



Analysis from the EMPA-REG OUTCOME® trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics.
Gert J Mayer, Christoph Wanner, Matthew R Weir, Silvio E Inzucchi, Audrey Koitka-Weber, Stefan Hantel, Maximilian von Eynatten, Bernard Zinman, David Z I Cherney. Kidney Int 2019
49
33

Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA-REG OUTCOME® trial.
Takashi Kadowaki, Masaomi Nangaku, Stefan Hantel, Tomoo Okamura, Maximilian von Eynatten, Christoph Wanner, Audrey Koitka-Weber. J Diabetes Investig 2019
34
33

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
33


SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, Kyungah Im, Erica L Goodrich, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Remo H M Furtado,[...]. Lancet 2019
33

Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers.
H J L Heerspink, E Johnsson, I Gause-Nilsson, V A Cain, C D Sjöström. Diabetes Obes Metab 2016
121
33

24-Hour Blood Pressure-Lowering Effect of an SGLT-2 Inhibitor in Patients with Diabetes and Uncontrolled Nocturnal Hypertension: Results from the Randomized, Placebo-Controlled SACRA Study.
Kazuomi Kario, Kenta Okada, Mitsutoshi Kato, Masafumi Nishizawa, Tetsuro Yoshida, Tsuguyoshi Asano, Kazuaki Uchiyama, Yawara Niijima, Tomohiro Katsuya, Hidenori Urata,[...]. Circulation 2018
83
33

Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus.
S Sha, D Polidori, T Heise, J Natarajan, K Farrell, S-S Wang, D Sica, P Rothenberg, L Plum-Mörschel. Diabetes Obes Metab 2014
145
33


Role of Pin1 protein in the pathogenesis of nonalcoholic steatohepatitis in a rodent model.
Yusuke Nakatsu, Yuichiro Otani, Hideyuki Sakoda, Jun Zhang, Ying Guo, Hirofumi Okubo, Akifumi Kushiyama, Midori Fujishiro, Takako Kikuch, Toshiaki Fukushima,[...]. J Biol Chem 2012
25
16

Prolyl isomerase Pin1 negatively regulates AMP-activated protein kinase (AMPK) by associating with the CBS domain in the γ subunit.
Yusuke Nakatsu, Misaki Iwashita, Hideyuki Sakoda, Hiraku Ono, Kengo Nagata, Yasuka Matsunaga, Toshiaki Fukushima, Midori Fujishiro, Akifumi Kushiyama, Hideaki Kamata,[...]. J Biol Chem 2015
22
16

Effects of SGLT2 inhibition in human kidney proximal tubular cells--renoprotection in diabetic nephropathy?
Usha Panchapakesan, Kate Pegg, Simon Gross, Muralikrishna Gangadharan Komala, Harshini Mudaliar, Josephine Forbes, Carol Pollock, Amanda Mather. PLoS One 2013
169
16

Aldosterone antagonists in monotherapy are protective against streptozotocin-induced diabetic nephropathy in rats.
Nora F Banki, Agota Ver, Laszlo J Wagner, Adam Vannay, Peter Degrell, Agnes Prokai, Renata Gellai, Lilla Lenart, Dorottya-Nagy Szakal, Eva Kenesei,[...]. PLoS One 2012
16
16

The Na+/Glucose Cotransporter Inhibitor Canagliflozin Activates AMPK by Inhibiting Mitochondrial Function and Increasing Cellular AMP Levels.
Simon A Hawley, Rebecca J Ford, Brennan K Smith, Graeme J Gowans, Sarah J Mancini, Ryan D Pitt, Emily A Day, Ian P Salt, Gregory R Steinberg, D Grahame Hardie. Diabetes 2016
160
16

Canagliflozin inhibits interleukin-1β-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms.
Sarah J Mancini, Daria Boyd, Omar J Katwan, Anastasiya Strembitska, Tarek A Almabrouk, Simon Kennedy, Timothy M Palmer, Ian P Salt. Sci Rep 2018
85
16

Inhibition of Pin1 alleviates myocardial fibrosis and dysfunction in STZ-induced diabetic mice.
Xue Liu, Ershun Liang, Xiuhui Song, Zhanhui Du, Yun Zhang, Yuxia Zhao. Biochem Biophys Res Commun 2016
23
16

Phosphate-Induced Renal Fibrosis Requires the Prolyl Isomerase Pin1.
Zhong-Jian Shen, Jie Hu, Kazuhiro Shiizaki, Makoto Kuro-o, James S Malter. PLoS One 2016
15
16

Physiological and Pathogenic Roles of Prolyl Isomerase Pin1 in Metabolic Regulations via Multiple Signal Transduction Pathway Modulations.
Yusuke Nakatsu, Yasuka Matsunaga, Takeshi Yamamotoya, Koji Ueda, Yuki Inoue, Keiichi Mori, Hideyuki Sakoda, Midori Fujishiro, Hiraku Ono, Akifumi Kushiyama,[...]. Int J Mol Sci 2016
25
16

SGLT2 Protein Expression Is Increased in Human Diabetic Nephropathy: SGLT2 PROTEIN INHIBITION DECREASES RENAL LIPID ACCUMULATION, INFLAMMATION, AND THE DEVELOPMENT OF NEPHROPATHY IN DIABETIC MICE.
Xiaoxin X Wang, Jonathan Levi, Yuhuan Luo, Komuraiah Myakala, Michal Herman-Edelstein, Liru Qiu, Dong Wang, Yingqiong Peng, Almut Grenz, Scott Lucia,[...]. J Biol Chem 2017
137
16



Pin1 induction in the fibrotic liver and its roles in TGF-β1 expression and Smad2/3 phosphorylation.
Jin Won Yang, Tran Thi Hien, Sung Chul Lim, Dae Won Jun, Hong Seok Choi, Jung-Hoon Yoon, Il Je Cho, Keon Wook Kang. J Hepatol 2014
32
16

The prolyl isomerase Pin1 increases β-cell proliferation and enhances insulin secretion.
Yusuke Nakatsu, Keiichi Mori, Yasuka Matsunaga, Takeshi Yamamotoya, Koji Ueda, Yuki Inoue, Keiko Mitsuzaki-Miyoshi, Hideyuki Sakoda, Midori Fujishiro, Suguru Yamaguchi,[...]. J Biol Chem 2017
14
16

Pin1 protein regulates Smad protein signaling and pulmonary fibrosis.
Zhong-Jian Shen, Ruedi K Braun, Jie Hu, Qifa Xie, Haiyan Chu, Robert B Love, Levi A Stodola, Louis A Rosenthal, Renee J Szakaly, Ronald L Sorkness,[...]. J Biol Chem 2012
30
16

Effects of RAAS Inhibitors in Patients with Kidney Disease.
Fan Zhang, Hong Liu, Di Liu, Yexin Liu, Huiqiong Li, Xia Tan, Fuyou Liu, Youming Peng, Hongqing Zhang. Curr Hypertens Rep 2017
40
16

Pin1 regulates TGF-beta1 production by activated human and murine eosinophils and contributes to allergic lung fibrosis.
Zhong-Jian Shen, Stephane Esnault, Louis A Rosenthal, Renee J Szakaly, Ronald L Sorkness, Pamela R Westmark, Matyas Sandor, James S Malter. J Clin Invest 2008
75
16

(1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment.
Hiroyuki Kakinuma, Takahiro Oi, Yuko Hashimoto-Tsuchiya, Masayuki Arai, Yasunori Kawakita, Yoshiki Fukasawa, Izumi Iida, Naoko Hagima, Hiroyuki Takeuchi, Yukihiro Chino,[...]. J Med Chem 2010
86
16



United States Renal Data System public health surveillance of chronic kidney disease and end-stage renal disease.
Allan J Collins, Robert N Foley, David T Gilbertson, Shu-Cheng Chen. Kidney Int Suppl (2011) 2015
183
16

Peptidyl-prolyl cis/trans isomerase NIMA-interacting 1 associates with insulin receptor substrate-1 and enhances insulin actions and adipogenesis.
Yusuke Nakatsu, Hideyuki Sakoda, Akifumi Kushiyama, Jun Zhang, Hiraku Ono, Midori Fujishiro, Takako Kikuchi, Toshiaki Fukushima, Masayasu Yoneda, Haruya Ohno,[...]. J Biol Chem 2011
45
16


Phosphorylation control of cardiac acetyl-CoA carboxylase by cAMP-dependent protein kinase and 5'-AMP activated protein kinase.
J R Dyck, N Kudo, A J Barr, S P Davies, D G Hardie, G D Lopaschuk. Eur J Biochem 1999
125
16

Unraveling reno-protective effects of SGLT2 inhibition in human proximal tubular cells.
Markus Pirklbauer, Ramona Schupart, Lisa Fuchs, Petra Staudinger, Ulrike Corazza, Sebastian Sallaberger, Johannes Leierer, Gert Mayer, Herbert Schramek. Am J Physiol Renal Physiol 2019
20
16

Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects.
Hiddo J L Heerspink, Mehul Desai, Meg Jardine, Dainius Balis, Gary Meininger, Vlado Perkovic. J Am Soc Nephrol 2017
191
16

Pharmacokinetics and Pharmacodynamics of Luseogliflozin, a Selective SGLT2 Inhibitor, in Japanese Patients With Type 2 Diabetes With Mild to Severe Renal Impairment.
Yoshishige Samukawa, Masakazu Haneda, Yutaka Seino, Takashi Sasaki, Atsushi Fukatsu, Yusuke Kubo, Yuri Sato, Soichi Sakai. Clin Pharmacol Drug Dev 2018
7
16


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.